Adalimumab SB5 gained approval in the European Union in 2017 and the US in 2019 based on evidence including a comparative clinical trial in patients with RA. Real-world studies have provided additional data on the use of SB5 in RA, AS, PsA, inflammatory bowel disease (IBD), psoriasis, HS, and uveitis. In both studies, most patients (78%-79%) and nurses (85%-86%) preferred the SB5